异基因造血干细胞移植后糖皮质激素耐药胃肠道急性移植物抗宿主病粪菌移植治疗19例临床研究
该研究纳入2017年3月至2022年3月徐州医科大学附属淮安医院29例allo-HSCT后糖皮质激素耐药GI-aGVHD患者,其中19例接受FMT(FMT组)、10例未接受(对照组)。FMT组完全缓解13例(68.4%)高于对照组2例(20.0%),差异有统计学意义(P<0.05);FMT后肠道菌群多样性增加并逐渐恢复至正常水平,未发生FMT相关感染。
要点
- FMT组完全缓解13例(68.4%)vs 对照组2例(20.0%),差异有统计学意义(P<0.05)。
- FMT后肠道微生物群多样性增加并逐渐恢复至正常水平,未发生FMT相关感染。
- FMT组治疗后IL-6低于对照组、IL-10高于对照组,REG3α低于对照组。
核心结论
- FMT是糖皮质激素耐药GI-aGVHD的有效、安全治疗方法。
- FMT可促进肠道菌群多样性的恢复、调节炎症因子和上调Treg细胞表达。
研究设计与样本
- 纳入2017年3月至2022年3月徐州医科大学附属淮安医院行allo-HSCT后发生糖皮质激素耐药GI-aGVHD的29例血液病患者。
- 19例行FMT治疗(FMT组),10例未接受FMT治疗(对照组)。
- 观察疗效及安全性,分析FMT治疗前后肠道菌群丰度、淋巴细胞亚群比例、外周血炎症因子及GVHD生物标志物的变化。
主要发现
- FMT后临床症状完全缓解13例(68.4%),对照组完全缓解2例(20.0%),差异有统计学意义(P<0.05)。
- FMT后肠道微生物群多样性增加,并逐渐恢复至正常水平,未发生FMT相关感染。
- 与对照组比较,FMT组治疗后CD3(+)、CD8(+)细胞占比降低,CD4(+)、Treg及CD4(+)/CD8(+)细胞比值升高(P值均<0.05)。
- FMT组IL-6浓度低于对照组[4.15(1.91~5.71)ng/L对6.82(2.40~8.91)ng/L,P=0.040],IL-10浓度高于对照组[12.11(5.69~20.36)ng/L对7.51(4.10~9.58)ng/L,P=0.024]。
- REG3α在发生GI-aGVHD时明显升高,FMT组治疗后REG3α水平低于对照组[30.70(10.50~105.00)μg/L对74.35(33.50~139.50)μg/L,P=0.021]。
临床怎么用
- 作者认为FMT是糖皮质激素耐药GI-aGVHD的有效、安全治疗方法,可促进肠道菌群多样性恢复、调节炎症因子和上调Treg细胞表达。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the clinical efficacy of fecal microbiota transplantation (FMT) for treating steroid-refractory gastrointestinal acute graft-versus-host disease (GI-aGVHD) . Methods: This analysis included 29 patients with hematology who developed steroid-refractory GI-aGVHD after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Huaian Hospital Affiliated to Xuzhou Medical University from March 2017 to March 2022. Among them, 19 patients underwent FMT treatment (the FMT group) and 10 patients did not (the control group). The efficacy and safety of FMT were assessed, as well as the changes in intestinal microbiota abundance, lymphocyte subpopulation ratio, peripheral blood inflammatory cytokines, and GVHD biomarkers before and after FMT treatment. Results: ① Complete remission of clinical symptoms after FMT was achieved by 13 (68.4%) patients and 2 (20.0%) controls, with a statistically significant difference (P<0.05). Intestinal microbiota diversity increased and gradually recovered to normal levels after FMT and FMT-related infections did not occur. ②The proportion of CD3(+) and CD8(+) cells in the FMT group after treatment decreased compared with the control group, and the ratio of CD4(+), regulatory T cells (Treg), and CD4(+)/CD8(+) cells increased (all P< 0.05). The interleukin (IL) -6 concentration in the FMT group was lower than that in the control group [4.15 (1.91-5.71) ng/L vs 6.82 (2.40-8.91) ng/L, P=0.040], and the IL-10 concentration in the FMT group was higher than that in the control group [12.11 (5.69-20.36) ng/L vs 7.51 (4.10-9.58) ng/L, P=0.024]. Islet-derived protein 3α (REG3α) was significantly increased in patients with GI-aGVHD, and the REG3α level in the FMT group was lower than that in the control group after treatment [30.70 (10.50-105.00) μg/L vs 74.35 (33.50-139.50) μg/L, P=0.021]. Conclusion: FMT is a safe and effective method for the treatment of steroid-refractory GI-aGVHD by restoring intestinal microbiota diversity, regulating inflammatory cytokines, and upregulating Treg cells. 目的: 探讨粪菌移植(FMT)治疗糖皮质激素耐药胃肠道急性移植物抗宿主病(GI-aGVHD)的临床疗效。 方法: 纳入2017年3月至2022年3月期间在徐州医科大学附属淮安医院行异基因造血干细胞移植(allo-HSCT)后发生糖皮质激素耐药GI-aGVHD的29例血液病患者,其中19例行FMT治疗(FMT组),10例未接受FMT治疗(对照组)。观察疗效及安全性,分析FMT治疗前后肠道菌群丰度、淋巴细胞亚群比例、外周血炎症因子及GVHD生物标志物的变化。 结果: ①13例患者(68.4%)在FMT后临床症状达到完全缓解,对照组2例患者(20.0%)达到完全缓解,差异有统计学意义(P<0.05)。FMT后肠道微生物群多样性增加,并逐渐恢复至正常水平,未发生FMT相关感染。②与对照组比较,FMT组治疗后CD3(+)、CD8(+)细胞占比降低,CD4(+)、调节性T细胞(Treg)及CD4(+)/CD8(+)细胞比值升高(P值均<0.05),IL-6浓度低于对照组[4.15(1.91~5.71)ng/L对6.82(2.40~8.91)ng/L,P=0.040],IL-10浓度高于对照组[12.11(5.69~20.36)ng/L对7.51(4.10~9.58)ng/L,P=0.024]。胰岛衍生蛋白3α(REG3α)在发生GI-aGVHD时明显升高,FMT组治疗后REG3α水平低于对照组[30.70(10.50~105.00)μg/L对74.35(33.50~139.50)μg/L,P=0.021]。 结论: FMT是糖皮质激素耐药GI-aGVHD的有效、安全治疗方法。FMT可促进肠道菌群多样性的恢复、调节炎症因子和上调Treg细胞表达。.
引用
- Zheng YY, Yang XT, Lin GQ, et al. [Clinical study of 19 cases of steroid-refractory gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with fecal microbiota transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 37550190. doi:10.3760/cma.j.issn.0253-2727.2023.05.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。